Aruna Bio Reports IND Clearance of AB126 from the US FDA for Neurological Indications
Shots:
- The US FDA has cleared the IND application of AB126 to conduct a P-Ib/IIa study for the treatment of acute ischemic stroke and expected to initiate in H1’24
- The P-Ib/IIa dose-ascending study investigating the safety, tolerability, and preliminary efficacy of AB126 (3 IV doses at low, medium, and high doses) for the treatment of acute ischemic stroke that has undergone a thrombectomy
- AB126, an unmodified neural-derived exosome, possesses an innate ability to cross the blood-brain barrier and exhibits anti-inflammatory and neuroprotective properties
Ref: Globenewswire | Image: Aruna Bio
Related News:- Cure Genetics Signs a Collaboration and License Agreement with Frametact to Develop Gene Therapy for Familial Neurological Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
